ClinicalTrials.gg
Active, not recruitingNCT05966480LUMUSUpdated Jul 21, 2026

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

A Phase 2 interventional study of Envudeucitinib and Placebo in SLE, sponsored by Alumis Inc. Active, not recruiting at 169 sites in 21 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-21.

Primary conditionLupus Erythematosus, SystemicRegistry: Autoimmune DiseasesReclassifiedWhy we changed it
Registry
Autoimmune Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lupus Erythematosus, Systemic
Why
  1. The study's title name Lupus Erythematosus, Systemic, a narrower term within Autoimmune Diseases.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Alumis Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
408
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 477 studies in Lupus Erythematosus, Systemic with a site in United States — 87 open to participants now, 127 under way, 28 of them phase 3. Lupus Erythematosus, Systemic · United States.

Enrollment
50th of 407
408 · median 70
Started
2023
with 22 others
Phase 2
120 of 477
10 open now
Primary completion
2026-06
later than 10 of 125 live
Registered
381st of 477
by date

Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, this one is the 50th largest by enrollment of the 407 interventional ones that give a count, is one of 23 that started in 2023, is one of 120 in phase 2, reaches primary completion later than 10 of the 125 other live ones, and was the 381st registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

87 of the 477 studies in Lupus Erythematosus, Systemic with a site in United States are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 477 studies in Lupus Erythematosus, Systemic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the clinical efficacy, safety, PK, and PD of multiple dose levels of ESK-001 compared with placebo in adult patients with SLE.

Read the detailed description

This study will consist of a 5 week screening period, 48 week treatment period, and a 4 week follow up period for a total of 57 weeks. Each participant will be randomized to receive ESK-001 or placebo for 48 weeks. An open label extension study will be available for those patients who complete the study.

03

Conditions studied

  • SLE

Keywords

  • Autoimmune Diseases
  • Immune System Diseases
  • Connective Tissue Diseases
  • Immune-mediated Diseases
  • Active Systemic Lupus Erythematosus
  • SLE
  • Lupus
  • LUMUS
  • Lupus Erythematosus, Systemic
04

In context

Lupus Erythematosus, Systemic Reclassified

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

This study's enrollment of 408 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.

Browse Lupus Erythematosus, Systemic studies →

Lead sponsor

Alumis Inc is the lead sponsor of 13 studies on the registry; none are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Compared within Lupus Erythematosus, Systemic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Autoimmune Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients with 6 or more months of SLE according to the 2019 EULAR/ACR criteria, have positive autoantibodies or low complement at screening, and have active SLE as measured by SLEDAI-2K of 6 or more, or 4 or more if joint involvement is present.

Patients need to be on treatment which can be:

  • A stable dose of oral (≤40 mg/day prednisone or equivalent) for a minimum of 2 weeks prior to signing of the form (ICF) at the Screening Visit. The dose of oral corticosteroid the patient is taking should not increase between screening and Week 0 (Day 1).
  • And/or antimalarial treatment (e.g., hydroxychloroquine, chloroquine, quinacrine),
  • And/or no more than 1 of the following conventional DMARDS:

    • Azathioprine ≤200 mg/day
    • Mycophenolate mofetil ≤2 g/day or mycophenolic acid ≤1.44 g/day
    • Oral, subcutaneous, or intramuscular (IM) methotrexate ≤20 mg/week.

Exclusion criteria

Exclusion Criteria:

  • Drug-induced SLE or other diseases that, in the opinion of the Investigator, are likely to confound efficacy assessments
  • Active, proliferative lupus nephritis that in the Investigator's opinion may require treatment not allowed by the protocol
  • Current disease other than SLE that, in the opinion of the Investigator, is likely to interfere with SLE disease activity assessments. Examples include severe fibromyalgia, severe osteoarthritis and severe cardiorespiratory diseases.
  • Active severe or unstable neuropsychiatric SLE including, but not limited to the following: aseptic meningitis; cerebral vasculitis; myelopathy; demyelination syndromes (ascending or transverse myelitis, acute inflammatory demyelinating polyradiculopathy); acute confusional state; impaired level of consciousness; psychosis; acute stroke or stroke syndrome; cranial neuropathy; new seizures; cerebellar ataxia; and mononeuritis multiplex.

    • That would make the patient unable to fully understand the ICF, or
    • Where, in the opinion of the Principal Investigator, protocol-specified SOC is insufficient and utilization of a more aggressive therapeutic approach not permitted in the protocol, is indicated
  • Known history of a primary immunodeficiency or an underlying condition such as infection or splenectomy that predisposes the patient to infection
  • Currently active, infection of any kind
  • Clinically significant chronic infection (eg, osteomyelitis, bronchiectasis) within 8 weeks prior to signing the ICF (chronic fungal nail infections are allowed)
  • Any infection requiring hospitalization or treatment with IV anti-infectives not completed at least 4 weeks prior to signing the ICF
  • Any infection requiring oral anti-infectives (including antivirals) within 2 weeks prior to Day 1
  • Any severe herpes infection at any time prior to Week 0 (Day 1), including, but not limited to, disseminated herpes (ever), herpes encephalitis (ever), recurrent herpes zoster (defined as 2 episodes within 2 years), or ophthalmic herpes (ever)

    • Active herpes zoster infection within 12 weeks of prior to signing the ICF
    • Active herpes simplex virus within 4 weeks of Day 1
  • Other protocol-defined inclusion/exclusion criteria apply
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
408 participants (actual)

Study arms

  • Experimental
    ESK-001 Dose Level 1

    ESK-001 administered as an oral tablet

    Drug: Envudeucitinib

  • Experimental
    ESK-001 Dose Level 2

    ESK-001 administered as an oral tablet

    Drug: Envudeucitinib

  • Experimental
    ESK-001 Dose Level 3

    ESK-001 administered as an oral tablet

    Drug: Envudeucitinib

  • Placebo comparator
    Placebo

    Placebo administered as an oral tablet

    Drug: Placebo

Interventions

07

What researchers measure

Primary outcomes

  1. To compare the effect on disease activity measured by the proportion of patients achieving British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) response at Week 48 between doses of ESK-001 and placebo

    Time frame: Week 48

Secondary outcomes

  1. To assess the safety and tolerability of multiple dose levels of ESK-001

    Safety and Tolerability will be assessed with clinical and laboratory assessments including blood tests for liver and kidney function, ECGs, hematological measures and physical examinations throughout the time of the study and safety follow up. The number and proportion of TEAEs, SAEs, AEs of greater than grade 3 severity and AEs of Clinical Interest will be recorded.

    Time frame: Week 48

  2. To compare the effect on disease activity measured by the proportion of patients achieving an SLE Responder Index of ≥4 (SRI[4]) response at Week 48

    Time frame: Week 48

  3. To compare corticosteroid use in patients at Week 48

    To compare the number and percentage of patients using corticosteroids and continuous summaries of dose used will be assessed as well as the frequency and percentage of patients able to taper corticosteroids and maintain low doses following taper.

    Time frame: Week 48

  4. To compare the effect on cutaneous disease activity measured by the proportion of patients with a CLASI activity score of ≥8 at baseline achieving ≥ 50% reduction in the CLASI activity score at Week 48 between doses of ESK-001 and placebo

    Time frame: Week 48

  5. To compare the effect on disease activity measured by the proportion of patients achieving BICLA responses at Week 48 between doses of ESK-001 and placebo by stratification groups

    Time frame: Week 48

  6. To compare the Lupus Low Disease Activity State (LLDAS) response between doses of ESK-001 and placebo at Week 48

    Time frame: Week 48

  7. To compare the annualized flare rate through Week 48

    Time frame: Week 48

  8. To use the SF-36 (Short Form-36 item QoL measure) to compare the effect on health-related quality of life (HRQOL) between doses of ESK-001 and placebo

    Efficacy: Comparing the effects of Esk-001 doses vs Placebo on Patient Reported Outcome (PRO) as it relates to Health-Related Quality of Life (HRQoL) as measured by self-reporting using the SF-36 (Short Form-36 item QoL measure) Questionnaire which uses a scale of 0 to 100. The higher numbers mean better health.

    Time frame: Week 48

  9. To use the SLE-specific Lupus Quality of Life (LQoL) questionnaire to compare the effect on health-related quality of life (HRQOL) between doses of ESK-001 and placebo

    Efficacy: Comparing the effects of Esk-001 doses vs Placebo on Patient Reported Outcome (PRO) as it relates to Health-Related Quality of Life (HRQoL) as measured by self-reporting using the SLE-specific Lupus Quality of Life (LQoL) questionnaire which uses a scale of 0 to 100. The higher numbers mean better health.

    Time frame: Week 48

  10. To compare disease-specific QoL between doses of ESK-001 and placebo

    Efficacy: To compare disease-specific QoL between doses of ESK-001 and placebo using the SLE Disease Activity Index 2000 (SLEDAI2K) measured on a scale of 0 to 105 where the higher numbers mean more disease activity.

    Time frame: Week 48

  11. To compare disease-specific QoL between doses of ESK-001 and placebo

    Efficacy: To compare disease-specific QoL between doses of ESK-001 and placebo using the British Isle Lupus Assessment Group 2004 (BILAG-2004) with a scale of A to E (A meaning very active disease and E no current or previous disease).

    Time frame: Week 48

  12. To compare disease-specific QoL between doses of ESK-001 and placebo

    Efficacy: To compare disease-specific QoL between doses of ESK-001 and placebo using the Physician's Global Assessment (PGA) evaluating disease response using the 4-point VAS (Visual Analog Scale) of 0 to 3 (0 means no flares and 3 means severe flare in disease).

    Time frame: Week 48

  13. To compare Fatigue measured by FACIT-F between doses of ESK-001 and placebo

    To compare patient-reported fatigue as measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaire between doses of ESK-001 and placebo, where the score range is 0 to 52 and a lower score indicates greater fatigue/worse outcome.

    Time frame: Week 48

  14. To compare patient global assessment of disease activity (PtGA) between doses of ESK-001 and placebo

    Efficacy: To compare disease-specific QoL between doses of ESK-001 and placebo using the PtGA (Patient Global Assessment) instrument. Patients record on a visual analog scale (VAS) how well or badly they feel as a result of the disease in their own estimation over the course of the study.

    Time frame: Week 48

08

Study locations

169 sites
  • Investigator Site #1046
    Anniston, Alabama 36207, United States
  • Investigator Site #1104
    La Jolla, California 92037, United States
  • Investigator Site #1050
    Los Alamitos, California 90720, United States
  • Investigator Site #1168
    Mission Hills, California 91345, United States
  • Investigator Site #1174
    Napa, California 94558, United States
  • Investigator Site #1061
    Upland, California 91786, United States
  • Investigator Site #1048
    Aventura, Florida 33180, United States
  • Investigator Site #1063
    Avon Park, Florida 33825, United States
  • Investigator Site #1176
    Bradenton, Florida 34209, United States
  • Investigator Site #1045
    Clearwater, Florida 33765, United States
  • Investigator Site #1055
    Coral Gables, Florida 33134, United States
  • Investigator Site #1097
    Coral Springs, Florida 33071, United States
  • Investigator Site #1091
    Daytona Beach, Florida 32117, United States
  • Investigator Site #1051
    DeBary, Florida 32713, United States
  • Investigator Site #1087
    Hollywood, Florida 33020, United States
  • Investigator Site #1135
    Kissimmee, Florida 34741, United States
  • Investigator Site #1060
    Miami, Florida 33136, United States
  • Investigator Site #1093
    Miami, Florida 33155, United States
  • Investigator Site #1057
    Miami, Florida 33176, United States
  • Investigator Site #1067
    Miami Lakes, Florida 33014, United States
  • Investigator Site #1090
    Plantation, Florida 33324, United States
  • Investigator Site #1089
    Tampa, Florida 33606, United States
  • Investigator Site #1170
    Atlanta, Georgia 30328, United States
  • Investigator Site #1052
    College Park, Georgia 30329, United States
  • Investigator Site #1204
    Chesterfield, Missouri 63017, United States
  • Investigator site #1209
    Las Vegas, Nevada 89102, United States
  • Investigator Site #1189
    Sparta, New Jersey 07871, United States
  • Investigator Site #1101
    Albuquerque, New Mexico 87102, United States
  • Investigator Site #1058
    Brooklyn, New York 11201, United States
  • Investigator Site #1088
    New York, New York 10032, United States
  • Investigator Site #1175
    Queens, New York 11001, United States
  • Investigator Site #1095
    Charlotte, North Carolina 28207, United States
  • Investigator Site #1056
    Charlotte, North Carolina 28210, United States
  • Investigator Site #1173
    Charlotte, North Carolina 28277, United States
  • Investigator Site #1171
    Philadelphia, Pennsylvania 19114, United States
  • Investigator Site #1062
    Pittsburgh, Pennsylvania 15224, United States
  • Investigator Site #1044
    Memphis, Tennessee 38119, United States
  • Investigator Site #1195
    Carrollton, Texas 75006, United States
  • Investigator Site #1049
    Colleyville, Texas 76034, United States
  • Investigator Site #1071
    Fort Worth, Texas 76177, United States
  • Investigator Site #1094
    Houston, Texas 77054, United States
  • Investigator Site #1169
    Houston, Texas 77095, United States
  • Investigator site #1178
    Houston, Texas 77386, United States
  • Investigator Site #1187
    Red Oak, Texas 75154, United States
  • Investigator site #1053
    San Antonio, Texas 78215, United States
  • Investigator Site #1186
    San Antonio, Texas 78229, United States
  • Investigator Site #1172
    Spring, Texas 77388, United States
  • Investigator Site #1194
    Tomball, Texas 77375, United States
  • Investigator Site #3023
    Buenos Aires, Buenos Aires C1114 AAH, Argentina
  • Investigator Site #3012
    CABA, Buenos Aires C1425, Argentina
  • Investigator Site #3001
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1221ADC, Argentina
  • Investigator Site #3016
    La Plata, Buenos Aires B1900, Argentina
  • Investigator Site #3008
    Mendoza, Mendoza Province M5500CPH, Argentina
  • Investigator Site #3009
    San Miguel de Tucumán, Tucman T4000BRD, Argentina
  • Investigator Site #3010
    San Miguel de Tucumán, Tucman T4000BRD, Argentina
  • Investigator Site #3015
    San Miguel de Tucumán, Tucumán Province T4000, Argentina
  • Investigator Site #5603
    Haskovo, 6300, Bulgaria
  • Investigator Site #5602
    Pleven, 2873, Bulgaria
  • Investigator Site #5525
    Plovdiv, 4003, Bulgaria
  • Investigator Site #5521
    Plovdiv, Bulgaria
  • Investigator Site #5529
    Rousse, 7002, Bulgaria
  • Investigator Site #5522
    Sofia, 1407, Bulgaria
  • Investigator Site #5547
    Sofia, 1463, Bulgaria
  • Investigator Site #3006
    Providencia, 7510586, Chile
  • Investigator Site #3002
    Santiago, 75500587, Chile
  • Investigator Site #3019
    Barranquilla, 11111, Colombia
  • Investigator Site #3011
    Barranquilla, 80020, Colombia
  • Investigator Site #3021
    Bogotá, 110221, Colombia
  • Investigator Site #3022
    Bogotá, 504, Colombia
  • Investigator Site #3020
    Cali, 760035, Colombia
  • Investigator Site #3003
    Chía, 250001, Colombia
  • Investigator Site #3014
    Medellín, 50034, Colombia
  • Investigator Site #5542
    Rijeka, 51000, Croatia
  • Investigator Site #5543
    Split, 21000, Croatia
  • Investigator Site #4012
    Aarhus, Denmark
  • Investigator Site #4011
    Køge, 4600, Denmark
  • Investigator Site #5516
    Tbilisi, 0168, Georgia
  • Investigator Site #5523
    Tbilisi, 102, Georgia
  • Investigator Site #5538
    Tbilisi, 112, Georgia
  • Investigator Site #5536
    Tbilisi, 114, Georgia
  • Investigator Site #5534
    Tbilisi, 180, Georgia
  • Investigator Site #5517
    Tbilisi, Georgia
  • Investigator Site #4003
    Leipzig, 4103, Germany
  • Investigator Site #4005
    Mainz, 55131, Germany
  • Investigator Site #4006
    Munich, 80336, Germany
  • Investigator Site #5548
    Debrecen, 4032, Hungary
  • Investigator Site #5544
    Gyula, Hungary
  • Investigator Site # 6015
    New Delhi, National Capital Territory of Delhi 110 029, India
  • Investigator Site #6005
    Ahmedabad, 380005, India
  • Investigator Site #6010
    Ahmedabad, 380006, India
  • Investigator Site #6016
    Ahmedabad, 380013, India
  • Investigator Site #6006
    Ahmedabad, 380015, India
  • Investigator Site #6001
    Bangalore, 560034, India
  • Investigator Site #6009
    Bengaluru, 560010, India
  • Investigator Site #6012
    Chandigarh, 160012, India
  • Investigator Site #6004
    Haryāna, 122001, India
  • Investigator Site #6013
    Jaipur, 302004, India
  • Investigator Site #6011
    Lucknow, 226014, India
  • Investigator Site #6008
    Nagpur, 440012, India
  • Investigator Site #6014
    Pune, 411007, India

Showing the first 100 of 169 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Jun 2026, 35 months.

Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 35 months is close to that.

Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2023
First posted
Jul 28, 2023
StartActual
Jun 26, 2023
Primary completionActual
Jun 23, 2026
CompletionEst.
Sep 1, 2027
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05966480
Lead sponsor
Alumis Inc
Responsible party
Sponsor
First posted
Jul 28, 2023
Start date
Jun 26, 2023
Primary completion
Jun 23, 2026
Completion
Sep 1, 2027 (estimated)
Last update
Jul 21, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Envudeucitinib

Start the discussion